Virbac strategy focuses on pet health, shares steady in the animal health sector

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-29, 14:31.

Virbac (FR0000031577) is a France-based veterinary pharmaceutical group that generates the majority of its revenue from products for companion animals such as dogs and cats. The stock is part of the global animal health peer universe alongside Zoetis and Elanco Veterinary Medicine, which are listed on the NYSE.

How Virbac positions its business

Virbac reports net revenue of 1.25 billion euros in 2025, according to its latest annual report, with approximately 60 percent derived from companion animal products and the remainder from food-producing animals. The group states that Europe and North America together contribute more than half of sales, highlighting its developed-market exposure and competition with Zoetis and Elanco in those regions.

According to Virbac, the company focuses on vaccines, parasiticides, dermatology and dental care, which are segments with recurring demand driven by pet ownership and the medicalization of animal health. The business is structured regionally, with dedicated subsidiaries and distribution networks in key markets such as France, the United States and Latin America.

Long-term strategy and sector peers

Virbac outlines a medium-term strategy centered on organic growth in companion animals, targeted acquisitions, and innovation in prevention-focused products. In the animal health sector, Zoetis reported annual revenue of 8.5 billion dollars for 2025 and Elanco around 4.1 billion dollars, underlining the significantly larger scale of these NYSE-listed peers.

Analyst coverage of the animal health sector frequently highlights structural growth drivers such as rising pet ownership, increased spending on veterinary care and innovation in biologics. For example, Zoetis is followed by major banks including Goldman Sachs and JPMorgan, which publish regular research on animal health market trends and competitive dynamics.

What the company sells

Virbac's portfolio includes parasiticides for dogs and cats, such as spot-on treatments against fleas and ticks, alongside vaccines against common canine and feline diseases. It also offers dermatology products and oral hygiene solutions under various brands sold through veterinarians and specialized pet pharmacies.

Where the stock trades today

The Virbac shares (FR0000031577) trade on Euronext Paris, where the latest verifiable quotation from exchange data shows a price around 420 euros in mid-June 2026. This implies a market capitalization in the low billion-euro range at recent levels.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. All data are based on publicly available sources believed to be reliable.